{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T18:48:39Z","timestamp":1791312519902,"version":"4.3.1"},"reference-count":15,"publisher":"S. Karger AG","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Nephrol"],"published-print":{"date-parts":[[2021]]},"abstract":"<jats:p>&lt;b&gt;&lt;i&gt;Background:&lt;\/i&gt;&lt;\/b&gt; Daprodustat is an oral agent that stimulates erythropoiesis by inhibiting the prolyl hydroxylases which mark hypoxia-inducible factor for degradation through hydroxylation. Its safety and efficacy (noninferiority) were assessed in this 52-week, open-label study. &lt;b&gt;&lt;i&gt;Methods:&lt;\/i&gt;&lt;\/b&gt; Japanese patients not on dialysis (ND) (&lt;i&gt;N&lt;\/i&gt; = 299) with anemia of CKD (stages G3, G4, and G5) with iron parameters of ferritin &amp;#x3e;100 ng\/mL or transferrin saturation &amp;#x3e;20% at screening were randomized to daprodustat or epoetin beta pegol (continuous erythropoietin receptor activator [CERA], also known as methoxy polyethylene glycol-epoetin beta). After initiation of the study, the daprodustat starting dose for erythropoiesis-stimulating agent (ESA)-na\u00efve participants was revised, and daprodustat was started at 2 or 4 mg once daily depending on baseline hemoglobin. ESA users switched to daprodustat 4 mg once daily. CERA was started at 25 \u03bcg every 2 weeks for ESA-na\u00efve patients and 25\u2013250 \u03bcg every 4 weeks for ESA users based on previous ESA dose. In both treatment groups, dose was adjusted every 4 weeks based on hemoglobin level and changed according to a prespecified algorithm. The primary endpoint was mean hemoglobin level during weeks 40\u201352 in the intention-to-treat (ITT) population. ESA-na\u00efve patients who entered before the protocol amendment revising the daprodustat starting dose were excluded from the ITT population. &lt;b&gt;&lt;i&gt;Results:&lt;\/i&gt;&lt;\/b&gt; Mean hemoglobin levels during weeks 40\u201352 were 12.0 g\/dL in the daprodustat group (&lt;i&gt;n&lt;\/i&gt; = 108; 95% confidence interval [CI], 11.8\u201312.1) and 11.9 g\/dL for CERA (&lt;i&gt;n&lt;\/i&gt; = 109; 95% CI 11.7\u201312.0); the difference between the groups was 0.1 g\/dL (95% CI \u22120.1 to 0.3 g\/dL). The lower limit of the 95% CI of the difference was greater than the prespecified margin of \u22121.0 g\/dL. The mean hemoglobin level was within the target range (11.0\u201313.0 g\/dL) during weeks 40\u201352 for 92% of participants in both groups. There was no meaningful difference in the frequencies of adverse events. &lt;b&gt;&lt;i&gt;Conclusions:&lt;\/i&gt;&lt;\/b&gt; Oral daprodustat was noninferior to CERA in achieving and maintaining target hemoglobin levels in Japanese ND patients. Daprodustat was well tolerated, with no new safety concerns identified.<\/jats:p>","DOI":"10.1159\/000513103","type":"journal-article","created":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T17:01:49Z","timestamp":1612890109000},"page":"26-35","source":"Crossref","is-referenced-by-count":66,"title":["Daprodustat Compared with Epoetin Beta Pegol for Anemia in Japanese Patients Not on Dialysis: A 52-Week Randomized Open-Label Phase 3 Trial"],"prefix":"10.1159","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7401-2934","authenticated-orcid":false,"given":"Masaomi","family":"Nangaku","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Hamano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadao","family":"Akizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiharu","family":"Tsubakihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reiko","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiko","family":"Okuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyo","family":"Kurata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Nagakubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel P.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukihiro","family":"Endo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander R.","family":"Cobitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2021,2,9]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1186\/s41100-017-0114-y"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2009.04.008"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199808273390903"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa065485"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfy013"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2015091009"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1097\/MNH.0000000000000431"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1159\/000496531"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2017.02.035"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfy014"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1159\/000454818"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1744-9987.2010.00836.x"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.272.32.20055"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/1744-9987.12962"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1813599"}],"container-title":["American Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/513103","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/513103","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T12:10:42Z","timestamp":1745410242000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000513103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,3,22]]},"published-print":{"date-parts":[[2021,3,30]]}},"URL":"https:\/\/doi.org\/10.1159\/000513103","archive":["Portico"],"relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.6084\/m9.figshare.13795589","asserted-by":"subject"}]},"ISSN":["0250-8095","1421-9670"],"issn-type":[{"value":"0250-8095","type":"print"},{"value":"1421-9670","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021]]}}}